A B S T R A C T Human growth hormone (hGH) is known to be a potent stimulator of somatomedin secretion in vivo. The induction of somatomedin by growth hormone has been difficult to study in vitro, however, because no organ containing a high concentration of sQmatomedin has been identified. Because fetal mouse explants have been shown to produce somatomedin in vitro, we have undertaken studies to determine whether postnatal human fibroblast monolayers also produce somatomedin, and if so, whether its production is regulated by other hormones. Quiescent human fibroblasts were exposed to serumfree minimum essential medium, and the medium was assayed for somatomedin concentration using a specific radioimmunoassay for somatomedin-C. A progressive rise in immunoreactive somatomedin to 0.08 U/ml per 105 cells per 24 h was observed over 72 h of incubation. This was an underestimation of the actual concentration of immunoreactive somatomedin since the amount measured following acid treatment was at least fourfold higher than in the untreated medium. Growth hormone stimulated immunoreactive somatomedin production in a dose-dependent manner: 5 ng hGH/ml = 0.1 U/ml per 105 cells; 50 ng hGH/ml = 0.25 U/ml per 105 cells. Platelet-derived growth factor and fibroblast growth factor were also stimulatory, but epidermal growth factor, thyroxine, or cortisol had no effect. Media that had been exposed to human fibroblasts stimulated DNA synthesis in BALB/c 3T3 fibroblasts (a cell type that does not produce somatomedin). Medium-derived immunoreactive somatomedin eluted from Sephacryl S-200 in two major peaks (150,000 and 8,000 mol wt).
one observed when whole serum was used. These studies provide a model system for studying the humoral and nonhumoral factors that control the biosynthesis of somatomedin by human tissues. Since immunoreactive somatomedin production may be a rate-limiting factor for fibroblast growth, the delineation of the hormonal control of somatomedin production should lead to a better understanding of the mechanisms controlling human fibroblast growth. INTRODUCTION The somatomedins, a family of growth hormonedependent, insulinlike peptide growth factors, have been shown to be mitogenic for a variety of types of cultured cells (1) (2) (3) (4) (5) (6) . Cartilage from various species and fibroblasts derived from chick (7) and mouse (8) embryos fail to synthesize DNA or undergo mitosis normally when incubated in somatomedin-deficient serum. Evidence has been published, however, that hypopituitary serum is as effective as normal serum in increasing thymidine incorporation (7) and mitosis (9) by cultured human fibroblasts. Although such variables as species of cell origin (7), culture conditions (10), or differences in the methods by which the serum is prepared (11) might account partially for these differences in somatomedin dependancy, other explanations must be considered. For example, the effect of reducing the somatomedin concentration may be masked by a synergism between the small amounts of residual somatomedin remaining in hypopituitary serum and peptides that are not growth-hormone dependent, such as platelet-derived growth factor (PDGF)1 (12) . Alternatively, it is possible that the effect of somatomedin deficiency in serum is masked by the IAbbreviations used in this paper: BSA, bovine serum albumin; DME, Dulbecco's modified minimum essential somatomedin production of the cultured cells themselves. Indeed, there are reports of production and release of growth factors into medium of cultured transformed cells (13) (14) (15) and cells that proliferate in very low serum concentrations (16) . Explants of fetal mouse and rat liver (17, 18) and a number of other fetal mouse tissues are able to secrete immunoreactive somatomedin into the culture medium. Atkison et al. (19) have reported recently that monolayer cultures of human embryonic lung fibroblasts likewise release immunoreactive somatomedin. Because immunoreactive somatomedin production might be a rate-limiting step for human fibroblast replication, we have assessed the capacity of cultured postnatal human fibroblasts to produce immunoreactive somatomedin. We have also observed the effects of human growth hormone and other mitogens contained in serum on immunoreactive somatomedin production.
METHODS
Human fibroblasts were purchased from the Human Mutant Genetic Cell Repository, Camden, N. J. Dermal fibroblasts (strain 498) from a normal 3-yr-old donor were used in these studies. BALB/c 3T3 fibroblasts were a gift of Dr. Charles Stiles. Dulbecco's modified minimum essential medium (DME) was purchased from Flow Laboratories, Inc., Rockville, Md. Eagle's minimum essential medium (MEM), fetal calf serum, penicillin, and streptomycin were purchased from GIBCO, Grand Island Biological Co., Grand Island, N. Y. All cultures were plated in plastic petri dishes (Falconi Labware, Div. Becton, Dickinson & Co., Oxnard, Calif.). Bovine serum albumin (Sigma Chemical Co., St. Louis, Mo., fraction V) was determined to be free of immunoreactive somatomedin-C when assayed at a concentration of 50 mg/ml.
[methyl-3H]Thymidine (6 Ci/mM) was purchased from New England Nuclear, Boston, Mass. Porcine insulin (PJ 5682) was a gift from Eli Lilly Company, Indianapolis, Ind. Immunochemical grade human growth hormone (hGH) (HS 1144) and bovine growth hormone (B-16) were obtained from the National Pituitary Agency, Baltimore, Md. The human hormone preparation has 0.97 U hGH/mg, <1% contamination by other proteins, and is free of fibroblast growth-factorlike biological activity (8) . The somatomedin-C used in these studies was purified to homogeneity as determined by multiple criteria (20) . Mouse epidermal growth factor and bovine fibroblast growth factor were purchased from Collaborative Research Inc., Waltham, Mass., and the manufacturer stated that they were >99% pure. PDGF was prepared by the following method: outdated human platelets were washed in 17 mM Tris HCI, pH 7.5, and concentrated by centrifugation. The platelet pellet was freeze-thawed, then boiled for 10 min. The boiled extract was centrifuged at 3,000 g for 30 min to remove particulate debris. The supematant fluid was further purified using CM Sephadex chromatography, Pharmacia Fine Chemicals, Piscataway, N. J. (21) . PDGF prepared in this manner is purified 250-fold over crude platelet homogenate and contains no somatomedin-C by radioimmunoassay. Human platelet poor plasma (PPP) was prepared by placing freshly drawn blood in prechilled plastic centrifuge tubes without anticoagulant and immediately centrifuging at 5,000 g. After removing the supematant fluid and repeating the centrifugation at 10,000 g for 30 min, the supemate was heated to 56C 'for 30 min and centrifuged at 5,000 g for 20 min. The resulting supematant fluid was dialyzed against 0.15 M sodium chloride and stored at -20°C until used. PPP prepared by this method is free of PDGF-like biological activity (12) . Hypopituitary PPP was obtained from two hypopituitary donors who were markedly deficient in immunoreactive somatomedin-C (<4 ng/ml), and was prepared in the same way as normal PPP.
Cell culture techniques. Cells were cultured in 10-cm dishes (Falcon 3001) in MEM containing 10% fetal calf serum (FCS) and were maintained in a humidified incubator containing 5% CO2. The medium was changed every 3rd d and the cells were harvested by trypsinization and replated once weekly (split ratio, 1:4). Both stock and test cultures were tested for mycoplasma contamination (22) and were found uncontaminated. To assess immunoreactive somatomedin production, fibroblasts (between the 8th and 12th passage) were plated in 1.5-cm wells (Falcon 3008) at a density of 5,000 cells/cm2 in MEM containing 10% FCS, penicillin (100 U/ml), and streptomycin (100 ;tg/ml). This medium was changed every 3 d until the cells reached confluency. 3 d after the last medium change, confluent monolayers were washed three times with serum-free MEM and incubated with 0.5 ml serum-free MEM containing 0.1% bovine serum albumin (BSA).2 The media were sampled at the times indicated in the Results section, either by removing of an aliquot and replacing it with an equal volume of MEM-0.1% BSA, or by removing the entire 0.5-ml incubation volume. Samples were immediately centrifuged at 1,400 g for 10 min to remove particulate debris and the supematant fluids were stored at -20'C until they were assayed for somatomedin content. Growth hormone and other mitogens were tested at various concentrations by adding the hormone (in MEM-0.1% BSA) to fibroblast monolayers that had been washed free of serum-containing medium. Samples were then processed and collected in the manner described above. At each time point, duplicate monolayers were washed twice, the cells were removed by trypsinization, and a 0.5-ml aliquot was placed in 9.5 ml of 0.15 M NaCl. Each sample was counted three times in a particle data counter (Coulter Electronics, Inc., Hialeah, Fla.) and the mean of six determinations was used as the cell number per monolayer.
Quantitation of immunoreactive somatomedin in culture media. The preparation of somatomedin-C used for iodination had a specific activity of 10,142 U/mg protein.3 It was iodinated with sodium 1251 (Amersham-Searle, Chicago, Ill.) by a chloramine T method (23) . Specific activities varied from 190-350 ,uCi/,ug. The iodinated hormone was purified by affinity chromatography using the IgG fraction of a rabbit anti-human somatomedin-C antibody coupled to Sephrose 4B (Pharmacia). The radioimmunoassay used rabbit antihuman somatomedin-C antibody in a final dilution of 1:12,000 (24) . This assay is highly specific for somatomedin-C and insulinlike growth factor I, which produce identical curves of competition (25) . Insulinlike growth factor II, somatomedin-A, or multiplication-stimulating activity 111-2 have potencies of 2.4, 5, and 1.2%, respectively. The immunoassay reference standard is an aliquot of the somatomedin preparation used for iodination that has been judged by multiple criteria to have a purity not <90% (20) .
In addition to measurement of immunoreactive soma- 2 Cells that were incubated in serum-free medium were 91% viable by trypan-blue exclusion. In addition, the detachment rate during this period was determined by cell counting to be <5%.
31 U is defined as the quantity of somatomedin contained in a pool of normal reference serum and is equivalent to 45 ng of the pure peptide. tomedin in unextracted fibroblast culture media, media were assayed after treatment with acid. In the acid treatment, 1.0 ml of the medium sample was incubated with 1.0 ml of 2 M acetic acid at 37°C for 30 min. The pH of the incubation mixture was 3.6. The acidified sample was then lyophilized to dryness and reconstituted in 0.03 M phosphate buffer, pH 7.5. The immunoreactive somatomedin content of both native and acid-treated media is expressed as U/ml per 105 cells.
Medium samples that had been acidified and neutralized were tested for their ability to compete with 125I-somatomedin-C for binding to placental membranes. Medium aliquots of 5-200 pl, '25I-somatomedin-C (20,000 cpm)/tube, and 200 ,ug placental membrane protein were incubated in Tris 0.05 M, pH 7.4, for 16 h. After this incubation the membranes were washed, and the bound radioactivity was detemined. The standard for this assay was a partially purified preparation of somatomedin-C which had been calibrated in the radioimmunoassay (RIA) against pure somatomedin-C.
Measurement of bioactive somatomedin in culture media. BALB/c 3T3 fibroblasts, which do not produce immunoreactive somatomedin, were plated at d-1,000 cells/microtest well in DME containing 10% FCS, penicillin (100 U/ml), and streptomycin (100 i&g/ml). Confluent monolayers were washed twice with serum-free DME and exposed for 5 h to DME containing partially purified PDGF (500 ng/well). This medium was removed and replaced with DME containing 5% hypopituitary PPP and either pure somatomedin-C (1-7 ng/ml) or conditioned MEM (10-60% of final volume). After 48 h incubation, DNA synthesis was measured by a previously described autoradiographic method (26) .
Characterization of immunoreactive somatomedin in media. 20 ml of medium that had been exposed to fibroblast monolayers for 48 h were dialyzed (Spectopor 3, mol wt cut off 3,500) against 1 liter of 0.025 M phosphate buffer, pH 7.4, for 48 h with four changes of buffer. The retained material was lyophilized to dryness, reconstituted with 1.0 ml water, applied to a 1.6 x 80-cm Sephacryl S-200 column, and eluted with 0.05 M phosphate buffer, pH 7.4. Each fraction was acidified for 30 min (pH adjusted to 3.6), lyophilized to dryness, reconstituted in 0.03 M phosphate buffer (pH 7.4), and assayed for immunoreactive somatomedin content. An additional 10-ml aliquot of medium was acidified with an equal volume of 2.0 M acetic acid, final pH 3.6, and lyophilized to dryness. The material was reconstituted in 0.5 ml acetic acid containing 10,000 cpm l5I-somatomedin-C, applied to a 1.6 x 20-cm Sephadex G-50 column and eluted with acetic acid. The fractions were lyophilized to dryness and reconstituted in 0.03 M P04 buffer, pH 7.4, before assay.
RESULTS
Measurement of immunoreactive somatomedin in fibroblast medium. Although confluent monolayer cultures of human fibroblasts were demonstrated to produce a peptide that reacted in our RIA, the amount of this material in medium was generally underestimated. When ,ul of medium that had been exposed to cells for 72 h were incubated with 1251_ somatomedin-C in immunoassay buffer, the curve of competition obtained was not parallel to that obtained using pure standard (Fig. 1) ,ul of Media or Pure SM-C Standard FIGURE 1 Dose-response curve for unextracted, conditioned medium. Medium that had been exposed to human fibroblasts for 24 h was assayed at multiple concentrations for somatomedin-C (SM-C) content. The results are plotted on a logit-log scale and the dose response of medium (0) is compared to the dose responses of pure somatomedin-C (0).
somatomedin binding activity, we were concerned that this lack of parallelism was the result of binding proteins in the fibroblast culture media. We also observed that when graded quantities of pure somatomedin-C were added to the medium, the recovery of the added peptide was incomplete (-23%). This incomplete recovery was not the result of degradation of somatomedin-C during immunoassay, because incubation of 125I-somatomedin-C with medium for 48 h (40 or 24°C) resulted in no loss ofbinding when samples were subsequently exposed to an excess of somatomedin antibody. Several perturbations of medium were tested to eliminate the effect of these interfering substances, and to achieve parallelism and full recovery. Heating media at 240, 370, or 56°C for variable periods of time had no effect. Reducing the pH of medium samples to 3.6 for 30 min and subsequent neutralization, however, produced dose-response curves parallel to the pure standard (Fig. 2) . 62% ofpure somatomedin-C that had been added to acidified media samples was recovered, and there was an eightfold enhancement of somatomedin activity over media which had not been acid treated. In subsequent studies, therefore, media were subjected routinely to acid treatment before assay. FIGURE 2 Dose-response curve for acid-treated medium. Medium (1.0 ml) that had been exposed to human fibroblasts for 24 h was acidified by adding 1.0 ml of 2.0 M acetic acid (final pH 3.6). After 30 min at 37°C, the mixture was neutralized using 0.015 ml of 0.1 N NaOH. The doseresponse curve obtained using acidified medium (0) is compared to that obtained using pure somatomedin-C (0).
immunoreactive somatomedin could be detected in the third wash. Medium samples removed at 24, 48, and 72 h showed a progressive rise in immunoreactive somatomedin concentration (Fig. 3) . (Table I) . Finally, sixth passage cultures were maintained in MEM containing 10% hypopituitary serum (<2 ng/ml somatomedin-C) for 3 wk. The monolayers were then washed extensively and incubated as usual in MEM-0.1% BSA. After 48 h, the concentration of immunoreactive somatomedin was 0.06 U/ml. Growth hormone stimulation of immunoreactive somatomedin production. When graded amounts of hGH were incubated for 24 h with confluent fibroblast monolayers containing only MEM-0.1% BSA, there was a dose-dependent (1-40 ng hGH/ml) increase in somatomedin production (Fig. 4) . These fibroblasts, therefore, are sensitive to hGH and display increases in immunoreactive somatomedin production at concentrations of growth hormone within the range normally found in human serum.
Other stimuli of immunoreactive somatomedin production by fibroblasts. In an additional series of experiments, confluent human fibroblasts were exposed to MEM-0.1% BSA containing either hGH (10 ng/ml), PDGF (500 ng/ml), or PDGF plus growth hormone. With these stimuli, cultured fibroblast media exhibited a progressive increase in immunoreactive somatomedin production over time (Fig. 5) . The combination of PDGF and growth hormone was additive at the concentrations tested. A variety of other factors had little effect on immunoreactive somatomedin production (Table II) . In addition to PDGF and hGH, stimulatory effects were noted when fibroblast growth factor was added, but not by cortisol, thyroxin, mouse epidermal growth factor, or porcine insulin. Bovine growth hormone, added over a concentration range 5-500 ng/ml, showed significant stimulation only at the 500 ng/ml concentration. This result indicates that bovine growth hormone is -1% as potent as hGH in inducing the formation of immunoreactive somatomedin in this system.
Biological and physicochemical properties of immunoreactive somatomedin produced by fibroblasts. To determine whether fibroblast-derived somatomedin can stimulate cell division, conditioned medium was added to BALB/c 3T3 cell monolayers in the presence of 5% hypopituitary PPP (<4 ng/ml immunoreactive somatomedin-C). For in DME for 5 h. These media were then removed, the monolayers were washed twice, and serum-free MEM that had been exposed to human fibroblast cultures for 48 h was added (in the percentage of the total volume listed) along with DME containing 5% hypopituitary PPP (total vol = 0.2 ml). The somatomedin content of the conditioned medium was 0.12 U/ml. This concentration of pure somatomedin-C has been shown by us and others (39) to stimulate fibroblast replication. After 48 h of incubation, each well was washed twice with 70% methanol and DNA synthesis was measured by autoradiography. 200 nuclei were counted in each well and each result (the mean of two wells) is expressed as the percentage of cells labeled. Additional wells received a known quantity of pure somatomedin-C standard instead of serum-free medium and the results were determined as described.
FIGURE 6 Gel filtration chromatography of medium on Sephacryl S-200. Medium that had been exposed to fibroblast cultures for 24 FIGuRE 7 Gel filtration chromatography of medium on Sephadex G-50. Medium which had been exposed to fibroblast cultures for 24 h was acidified (pH 3.6) and incubated for 18 h at 40C with 125I-somatomnedin-C (SM-C). This mixture was applied to a Sephadex G-50 column (20 x 1.6 cm) and eluted with acetic acid, pH 3.6. *, ODmo; 3, somatomedin ( (31) , macrophage growth factor (32) , and nerve growth factor (33) are produced by a variety of cultured cells. Cultured human fibroblasts have also been reported to produce a small peptide which stimulates endothelial cell division (34) and a macromolecule which enhances fibroblast attachment and stimulates replication in the presence of serum (35) . The (37) , it can be assumed that this tissue and perhaps others require blood-borne somatomedin for growth.
Preliminary studies indicate that a large portion of the immunoreactivity in cultured fibroblast medium is in an acid-stable, high molecular weight form. Similarities between this material and somatomedin-C purified from human plasma are suggested by the findings that the former (a) reacts with specific somatomedin-C antiserum, (b) crossreacts with somatomedin-C in the placental membrane radioreceptor assay, and (c) stimulates DNA synthesis in BALB/c 3T3 cells, which require the addition of somatomedin-C for replication. (17) ; however, the loss of 125I-somatomedin-C is contrary to results reported using human serum (38) . Since acid treatment does not result in conversion to a lower molecular weight form, its enhanced apparent immunoreactivity may result from better access of antibody to previously inaccessible somatomedin. Alternatively, some of the apparent immunoreactivity in the macromolecular fraction after acid treatment could result from interference of binding proteins in the RIA. This, however, appears unlikely because we observed parallelism between pure somatomedin-C and the acidtreated media and there is no 125I-somatomedin-C binding on gel chromatography. The major question concerning growth hormone's mechanism of action has been whether it stimulates cell replication directly, or acts through the induction of an intermediary substance such as somatomedin. Our results seem to strenghten the possibility of an indirect action. They demonstrate that the growth hormone, at concentrations comparable to those in human serum, stimulates cultured postnatal human fibroblasts to produce immunoreactive somatomedin. We have presented evidence recently that supports the hypothesis that somatomedin mediates the growthpromoting effects of growth hormone on cultured cells (39) . Specifically, we have observed that when medium containing hypopituitary PPP and growth hormone is removed and replenished every 2 h, replication of fibroblast cultures does not proceed at a normal rate.
Frequent changing of medium containing hypopituitary PPP and purified somatomedin-C, however, allows replication to proceed normally. These observations suggest that somatomedin production is necessary for normal fibroblast replication and the effect of growth hormone on fibroblasts is mediated through somatomedin production.
The potential importance of growth hormone-regulated immunoreactive somatomedin production by fibroblasts is that it might be the mechanism whereby growth hormone stimulates generalized cell growth. In contrast, stimulation of fibroblast immunoreactive somatomedin production by PDGF represents a nongrowth hormone-dependent mechanism by which fibroblast replication in culture could be stimulated. PDGF has been proposed as a growth factor which stimulates the rapid proliferation of fibroblasts during wound healing (40) . Stimulation of immunoreactive somatomedin production by PDGF could be one mechanism by which these events occur.
The system we have used for assessing immunoreactive somatomedin production has a number of uses. In addition to serving as a tool for the study of the hormonal control of immunoreactive somatomedin biosynthesis, it could be useful in assessing nonhormonal factors that regulate immunoreactive somatomedin production, and as an alternate means for determining the biological potency of growth hormone preparations.
There is evidence that fibroblast growth factor stimulates cellular proliferation by a mechanism similar to PDGF (8) . The capacity of a highly purified fibroblast growth factor preparation to substitute in our system for partially purified PDGF suggests that a single peptide in the platelet factor preparation may be responsible for stimulation of immunoreactive somatomedin production. The failure of epidermal growth factor, thyroxin, and insulin to stimulate immunoreactive somatomedin production suggests that the process is specific for certain peptides and implies that epidermal growth factor and insulin stimulate mitosis through mechanisms independent of immunoreactive somatomedin production. Our studies indicate that bovine growth hormone is a weak stimulator of immunoreactive somatomedin production. The concentrations of bovine growth hormone required are comparable to those necessary to compete with hGH for binding to receptors in human tissue (41) .
The observation that hypopituitary serum is as potent as normal serum in stimulating fibroblast replication suggests that immunoreactive somatomedin production by the fibroblast cultures may be nullifying any differences in the intrinsic mitogenic capacity of these two types of sera. The findings of Moses et al. (7) , that hypopituitary serum stimulates DNA synthesis by cultured cells, could be explained if their hypopituitary test serum contained enough PDGF to stimulate in vitro production of immunoreactive somatomedin that, in turn, stimulated proliferation of their cultured fibroblasts. Alternatively, other somatomedins that are slightly growth hormonedependent and, therefore present in hypopituitary serum, may stimulate replication in this cell type.
Although immunoreactive somatomedin generally has been considered to be a blood-borne hormone with widespread stimulatory effects on cell proliferation, our findings indicate that fibroblast-derived somatomedin may regulate proliferation of selected cell types at or near its site of production. Such local regulation could provide a mechanism whereby focal cellular proliferation could be coordinated without stimulation of adjacent tissues. Such a mechanism might be an important component of normal physiologic processes such as wound healing, or in disorders of cellular proliferation such as atherosclerosis.
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